(Gemtuzumab)Biosimilar Reference Antibody-GS40298 新品

货号：GS40298

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) approved for the treatment of acute myeloid leukemia (AML). It consists of a humanized monoclonal IgG4 antibody linked to a potent cytotoxic payload, calicheamicin, via a cleavable linker. Gemtuzumab ozogamicin functions as a targeted chemotherapy agent. The antibody component specifically binds to the CD33 antigen on the surface of AML blasts and leukemia stem cells. Upon binding, the ADC is internalized, and the linker is cleaved within the lysosome, releasing the calicheamicin payload. Calicheamicin causes double-strand DNA breaks, leading to tumor cell death. Its approval marked the first ADC for cancer therapy and a significant, though complex, advancement in AML treatment.